Circulating Tumor Cells Global Market 2018: Key Players – Menarini-Silicon Biosystems, Qiagen (Adnagen), Clearbridge Biomedics, Celsee, Fluidigm

Circulating Tumor Cells Industry

Description

Wiseguyreports.Com Adds “Circulating Tumor Cells -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

This report studies the global Circulating Tumor Cells market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Circulating Tumor Cells market by companies, region, type and end-use industry.

Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.

The classification of Circulating Tumor Cells (CTCs) products includes CTC enrichment, CTC detection and CTC analysis, and the revenue proportion of CTC enrichment in 2016 is about 43.74%.

North America is the largest supplier of CTCs Products, with a revenue market share nearly 53.18% in 2016. Europe is the second largest supplier of CTCs products, enjoying revenue market share nearly 28.01% in 2016.

Growth of the global CTCs market is mainly driven by increasing prevalence of cancer globally. Increasing prevalence of various cancers such as breast cancer, prostate cancer and lung cancer is expected to drive growth of the CTCs test market over the forecast period.
FDA approvals for various non-invasive diagnostic tests to detect cancer are set to define the regulatory landscape for CTCs tests. Companies in the CTCs market space are expected to invest more on test kits and cost containment procedures to provide innovative diagnostic solutions to the oncologists and physicians for detecting metastasis.

In 2017, the global Circulating Tumor Cells market size was 1220 million US$ and it is expected to reach 3560 million US$ by the end of 2025, with a CAGR of 14.3% during 2018-2025.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3267428-global-circulating-tumor-cells-market-size-status-and-forecast-2025

This report focuses on the global top players, covered

Menarini-Silicon Biosystems 
Qiagen(Adnagen) 
Clearbridge Biomedics 
Celsee 
Fluidigm 
ApoCell 
Greiner Bio-one GmbH 
Advanced Cell Diagnostics 
Aviva Biosciences 
Fluxion Biosciences 
Sysmex Corporation 
Epic Sciences 
Cynvenio 
CytoTrack 
Ikonisys 
Vortex BioSciences 
Gilupi 
Biocept 
ScreenCell 
ANGLE

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India

Market segment by Type, the product can be split into
CTC Enrichment
CTC Detection
CTC Analysis

Market segment by Application, split into
Breast Cancer
Prostate Cancer
Colorectal Cancer
Other

Leave a Query @ https://www.wiseguyreports.com/enquiry/3267428-global-circulating-tumor-cells-market-size-status-and-forecast-2025

 

Table of Contents

Global Circulating Tumor Cells Market Size, Status and Forecast 2025
1 Industry Overview of Circulating Tumor Cells
1.1 Circulating Tumor Cells Market Overview
1.1.1 Circulating Tumor Cells Product Scope
1.1.2 Market Status and Outlook
1.2 Global Circulating Tumor Cells Market Size and Analysis by Regions (2013-2018)
1.2.1 United States
1.2.2 Europe
1.2.3 China
1.2.4 Japan
1.2.5 Southeast Asia
1.2.6 India
1.3 Circulating Tumor Cells Market by Type
1.3.1 CTC Enrichment
1.3.2 CTC Detection
1.3.3 CTC Analysis
1.4 Circulating Tumor Cells Market by End Users/Application
1.4.1 Breast Cancer
1.4.2 Prostate Cancer
1.4.3 Colorectal Cancer
1.4.4 Other

....

3 Company (Top Players) Profiles
3.1 Menarini-Silicon Biosystems
3.1.1 Company Profile
3.1.2 Main Business/Business Overview
3.1.3 Products, Services and Solutions
3.1.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.2 Qiagen(Adnagen)
3.2.1 Company Profile
3.2.2 Main Business/Business Overview
3.2.3 Products, Services and Solutions
3.2.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.3 Clearbridge Biomedics
3.3.1 Company Profile
3.3.2 Main Business/Business Overview
3.3.3 Products, Services and Solutions
3.3.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.4 Celsee
3.4.1 Company Profile
3.4.2 Main Business/Business Overview
3.4.3 Products, Services and Solutions
3.4.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.5 Fluidigm
3.5.1 Company Profile
3.5.2 Main Business/Business Overview
3.5.3 Products, Services and Solutions
3.5.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.6 ApoCell
3.6.1 Company Profile
3.6.2 Main Business/Business Overview
3.6.3 Products, Services and Solutions
3.6.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.7 Greiner Bio-one GmbH
3.7.1 Company Profile
3.7.2 Main Business/Business Overview
3.7.3 Products, Services and Solutions
3.7.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.8 Advanced Cell Diagnostics
3.8.1 Company Profile
3.8.2 Main Business/Business Overview
3.8.3 Products, Services and Solutions
3.8.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.9 Aviva Biosciences
3.9.1 Company Profile
3.9.2 Main Business/Business Overview
3.9.3 Products, Services and Solutions
3.9.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.10 Fluxion Biosciences
3.10.1 Company Profile
3.10.2 Main Business/Business Overview
3.10.3 Products, Services and Solutions
3.10.4 Circulating Tumor Cells Revenue (Million USD) (2013-2018)
3.11 Sysmex Corporation
3.12 Epic Sciences
3.13 Cynvenio
3.14 CytoTrack
3.15 Ikonisys
3.16 Vortex BioSciences
3.17 Gilupi
3.18 Biocept
3.19 ScreenCell
3.20 ANGLE

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=3267428

Continued...                       

 

Contact Us: [email protected] Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

 

 

Posted by on Friday July 06 2018, 9:15 AM EST. All trademarks acknowledged. Filed under Uncategorized. Comments and Trackbacks closed. Follow responses: RSS 2.0

Comments are closed

Featured Press Releases

Log in